www.3sbio.com 提示:

本信息仅供医学专业人士参考,如果您是医学专业人士,请点击确定后进入。 如果不是,请点击取消。

取消 确定

Establishing a Solid Future for 3SBio through Transparent Management

Good corporate governance is the foundation of corporate development

The 3SBio’s governance philosophy stems from our company mission - to make the greatest value for patients, customers, colleagues, investors, business partners and society.
Below please find the biography of Directors, overview of the Board committees, and corporate governance documents.
The board of directors includes seven directors, of which two are executive directors, two non-executive directors and three are independent non-executive directors.

Dr. LOU Jing

Chairman, executive director and CEO

Responsible for Group strategic development and planning, overall operation management and major decision-making

Dr. LOU Jing, was appointed as a Director on 5 September 2006 and was redesignated as an executive Director on 27 November 2014. He was appointed as the chairman of the Board on 1 April 2012. Dr. Lou is also the chief executive officer of the Company. He is responsible for the strategic development and planning, overall operational management and major decision making of the Group. He is a co-founder of the Group and joined Shenyang Sunshine Pharmaceutical Company Limited (“Shenyang Sunshine”) as a director of R&D in September 1995.


Dr. Lou also holds the following positions with other members of the Group:
1) director and chairman of the board of Collected Mind Limited (集思有限公司, “Collected Mind”);
2) director of Hongkong Sansheng;
3) director of Excel Partner Holdings Limited (特隆控股有限公司, “Excel Partner”);
4) director of Ample Harvest Investments Limited (溢丰投资有限公司, “Ample Harvest”);
5) director, chief executive officer and president of Shenyang Sunshine and chairman of the board of Shenyang Sunshine;
6) director and general manager of Liaoning Sunshine Bio-Pharmaceutical Company Limited (辽宁三生医药有限公司, “Liaoning Sunshine”);
7) director and chairman of the board of Taizhou Huan Sheng Investment Management Company Limited (泰州环晟投资管理有限公司, “Taizhou Huan Sheng Investment”);
8) executive director of Shenzhen Baishitong Technology Development Company Limited (深圳市百士通科技开发有限公司, “Shenzhen Baishitong”);
9) chairman of the board of Shenzhen Sciprogen Bio-pharmaceutical Co., Ltd. (“Sciprogen”);
10) chairman of the board of Guangdong Sciprogen Bio-pharmaceutical Technology Co., Ltd. (广东赛保尔生物医药技术有限公司, “Guangdong Sciprogen”);
11) chairman of the board of Guangdong Sunshine Pharmaceutical Co., Ltd. (广东三生制药有限公司);
12) director of Gains Prestige Limited (泽威有限公司, “Gains Prestige”);
13) director of Strategic International Group Limited (“Strategic International”);
14) director and chairman of the board of Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“Sunshine Guojian”);
15) director and chairman of the board of Shanghai Xingsheng Pharmaceutical Company Limited (“Xing Sheng”);


Dr. Lou has been highly active in pharmaceutical research and has made substantial contribution to the Group’s R&D of pharmaceutical products. Dr. Lou was the leading scientist and principal investigator in the Group’s successful development of EPIAO and TPIAO. He co-invented a “preparation process for recombinant human thrombopoietin” and a “method for improving the stability of polypeptides in human bodies and its application” in 2000 and 2001, respectively. He has published in a number of academic journals on microbiology and medicinal biotechnology. His research has been recognized with various awards. In 2006, he was awarded the “First Prize of Shenyang Science and Technology Progress Award” (沈阳市科学技术进步一等奖) for his research on recombinant human thrombopoietin. In 2007, he was awarded the “Third Prize of Liaoning Province Scientific and Technological Achievements” (辽宁省科学成果转化三等奖) for his contribution to the industrialization of production of recombinant human thrombopoietin. In 2017, he was awarded “Liaoning Province Outstanding Entrepreneur” and “Friendship Award of Liaoning Province”. Dr. Lou obtained a Medical Doctor degree (M.D.) in clinical medicine from Shanghai Second Military Medical University in July 1985. He conducted post-doctoral research at the National Institutes of Health of the United States after obtaining a Ph.D. degree in molecular and cell biology from Fordham University in the United States in February 1994. He also obtained an Executive Master of Business Administration from China Europe International Business School (中欧国际工商学院) in September 2008.

Ms. SU Dongmei

Executive director and senior vice president

Ms. SU Dongmei was appointed as a Director on 11 June 2012 and was re-designated as an executive Director on 27 November 2014. Ms. Su is also the Company’s senior vice president and the general manager of Shenyang Sunshine. She is responsible for strategic direction of the Group. Ms. Su joined Shenyang Sunshine as a scientist of the research and development department in January 1993, and served as a director of the R&D department from 1997 to 2006. She subsequently served as the chief technology officer responsible for R&D and manufacturing process engineering of Shenyang Sunshine from 2006 to 2008. Ms. Su was promoted to vice president of Shenyang Sunshine in April 2008. Ms. Su served as a director of Shenyang Sunshine from August 2007 to June 2013, and was re-appointed on 18 July 2016. She also served as a director of Hongkong Sansheng from November 2009 to November 2014.


Ms. Su also holds the following positions with other members of the Group: (i) senior vice president and general manager of Shenyang Sunshine; (ii) supervisor of Liaoning Sunshine; (iii) director of Sciprogen; (iv) director of Guangdong Sciprogen; (v) director of Guangdong Sunshine; and (vi) director of Strategic International.


Ms. Su obtained a Bachelor’s degree in Biochemistry from Jilin University (吉林大學) in July 1992 and a Master’s and a Doctorate degree in Microbiology and Pharmacology from Shenyang Pharmaceutical University (瀋陽藥科大學) in June 2001 and July 2010, respectively. She has published in a number of academic journals on microbiology and medicinal biotechnology.

Mr. HUANG Bin

Non-executive director

Mr. HUANG Bin was first appointed as a Director on 5 September 2006 and ceased to be a Director on 29 May 2013. Mr. Huang was re-appointed as an executive Director on 27 November 2014, and was re-designated as a non-executive Director on 20 June 2019. Mr. Huang joined Shenyang Sunshine in 1993 as a manager of the human resources department.


Mr. Huang also holds the following positions (in a non-executive capacity) with other members of the Group: (i) director and vice president of Shenyang Sunshine; and (ii) director and general manager of Taizhou Huan Sheng Investment.


Mr. Huang received a diploma in Engineering from Northeast University (東北大學) in July 1987. He attended a one-year training program in business management in Tsinghua University (清華大學) from April 2000 to April 2001.

Mr. TANG Ke

Non-executive director

Mr. TANG Ke was appointed as a non-executive Director on 10 February 2020. He has more than 15 years of work experience in the investment sector. Mr. Tang joined CITIC Private Equity Funds Management Co., Ltd (中信產業投資基金管理有限公司, “CITIC PE”) in 2013 and had held various positions, including Vice President and Managing Director, before he became in charge of the investment department of the healthcare sector at CITIC PE. Mr. Tang has substantial experience in corporate investment, strategic planning, capital operation and corporate management. Mr. Tang served as an Associate and Executive Director at the investment banking division of Goldman Sachs Gao Hua from 2008 to 2011 and later served as an Investment Manager at the Principal Investment Department of Goldman Sachs Group from 2012 to 2013.


Mr. Tang also serves as a non-executive Director of Acotec Scientific Co. Ltd (北京先瑞達醫療科技有限公司)(previously as its chairman of the board of directors and its legal representative), and as the chairman of the board of directors of Spectrum Dynamics Medical Group Limited, Changzhou Dingjian Medical Limited (常州鼎健医疗器械有限公司), Shanghai Guang Mai Medical Technology limited (上海光脉医疗科技有限公司), and Beijing EverLife Healthcare Hospital Management Company Limited (北京長生眾康醫院管理有限公司), respectively. He was a director in Biosensors International Group, Ltd. (a company formerly listed on Singapore Exchange Securities Trading Limited which was subsequently delisted in 2016) from 2016 to 2018. Mr. Tang also served as a director of Bluesail Medical Co., Ltd.* (藍帆醫療股份有限公司) (a company listed on the Shenzhen Stock Exchange with stock code 002382) from September 2018 to May 2020.


Mr. Tang obtained his Bachelor of Arts from Southeast University and his Master of Business Administration from the Kellogg School of Management of the Northwestern University.


Mr. PU Tianruo

Independent non-executive director

Mr. PU Tianruo was appointed as an independent non-executive Director on 23 May 2015, with such appointment taking effect on 1 June 2015. He is responsible for participating in decision-making and advising on issues relating to the Company’s significant events and corporate governance. Previously, he served as an independent Director and the audit committee chair of the Company from 1 September 2012 to 29 May 2013.


Mr. Pu has substantial experience in accounting and finance. He has served as an independent non-executive director of several companies, including Autohome Inc. (a company listed on the NYSE with symbol ATHM) since December 2016, and Renren Inc. (a company listed on the NYSE with symbol RENN) since December 2016, Kaixin Auto (a company listed on the NASDAQ with symbol KXIN), One Connect Financial Technology (a company listed on the NYSE with symbol OCFT) since December 2019, and Luckin Coffee. Mr. Pu was previously the independent non-executive director of JMU Limited (a company listed on the NASDAQ with symbol JMU) and the chief financial officer of Zhaopin Ltd. (a company listed on the NYSE with symbol ZPIN). Mr. Pu obtained a Bachelor’s degree in English from China Foreign Affairs University (外交學院) in July 1991, a Master’s degree in Accounting from the University of Illinois, College of Business Administration in May 1996 and a Master of Business Administration degree from Northwestern University Kellogg School of Management in June 2000.

Dr. David Ross PARKINSON

Independent non-executive director

Mr. David Ross PARKINSON was appointed as an independent non-executive Director on 23 May 2015, with such appointment taking effect on 1 June 2015. He is responsible for participating in decision-making and advising on issues relating to the Companys significant events and corporate governance.


Mr. Parkinson has served as a director of ESSA Pharma Inc. (a company listed on the NASDAQ with symbol EPIX) since June 2015, and as its president and chief executive officer since January 2016. He also serves as a director of CTI BioPharma, Inc. and of Angiocrine Bioscience. He is the co-founder and chairman of the board of Refuge Biotechnology, Inc. He served as a director of Cerulean Pharma, Inc. (a company listed on the NASDAQ with symbol CERU) from October 2014 to July 2017, of Threshold Pharmaceuticals, Inc. (a company listed on the NASDAQ with symbol THLD) from May 2010 to July 2017, and of Tocagen Inc. (previously listed on the Nasdaq with symbol TOCA) from May 2015 to June 2020. He served as a venture advisor at New Enterprise Associates, a venture capital firm from 2007 to 2012. Mr. Parkinson served as the president and chief executive officer at Nodality, Inc., a biotechnology company focused on personalized medicine. Previously, he served as senior vice president and head of Oncology R&D at Biogen Idec, as vice president and head of the Oncology Therapeutic Area at Amgen Inc. (a company listed on the NASDAQ with symbol AMGN), and as vice president and head of global clinical oncology development at Novartis. Mr. Parkinson has led teams successfully developing a number of cancer drugs, including Gleevec, Femara, Zometa, and Vectibix. He served as a director of the American Association for Cancer Research (AACR) from 2006 to 2009, and Chairman of AACRs Finance Committee from 2001 to 2016. He also served on the National Cancer Policy Forum of the Institute of Medicine from 2005 to 2011. Mr. Parkinson has received multiple awards and honors, including the top innovator award from the Multiple Myeloma Research Foundation in 2012 and the Wiley Medal from the U.S. Food and Drug Administration in 1997. He delivered the 12th Andrew H. Weinberg Memorial Lecture at the Harvard University School of Medicine in 2008. Mr. Parkinson obtained a Doctor of Medicine degree (M.D.) at the University of Toronto Faculty of Medicine in 1974.



Dr. WONG Lap Yan

Independent non-executive director

Dr. WONG Lap Yan was appointed as an independent non-executive Director on 8 October 2019. Dr. Wong is a Chartered Biologist and Fellow of the Royal Society of Biology and a Chartered Scientist of the Science Council of the United Kingdom. Dr. Wong has over 20 years of work experience with various highly respectable healthcare and biopharmaceutical companies, genetic services providers and academia in biology, including conducting antibody cancer research in translational oncology at Genentech Inc. (formerly listed on NYSE: DNA and now a subsidiary of Roche), research in pharmacokinetics and drug metabolism at Amgen Inc. (listed on NASDAQ: AMGN) and pharmaceutical research at SRI International (a scientific research institute established by the trustees of Stanford University) in the United States. His research work has contributed to the discovery, research and development of cancer target therapy drugs, including Bevacizumab (Avastin) and Vemurafenib (Zelboraf), which are medication used to treat different types of cancers and specific eye diseases. He has published numerous medical research articles and abstracts in journals on different topics, including cancer and nutritional science, which have been cited extensively by peer scientists and researchers. Dr. Wong has also served as a Postdoctoral Fellow at the Faculty of Medicine at The University of Hong Kong and as a Chief Executive Officer of a biotechnology company in Hong Kong. Dr. Wong is now the Chief Scientific Officer and Principal Scientist of Alom Intelligence Limited that offers deep learning technology and analytical solutions relating to healthcare and financial data, and a director and founder of Cannan Biotech Limited that offers biotech and A.I. technology consultancy services. Dr. Wong obtained his Bachelor of Science in Human Biology from the University of Toronto, Canada and Doctor of Philosophy in Biological Sciences from The University of Hong Kong.


Dr. LOU Jing

Chairman, executive director and CEO

Responsible for Group strategic development and planning, overall operation management and major decision-making

  • Ms. SU Dongmei

    Executive director and senior vice president

  • Mr. HUANG Bin

    Non-executive director

  • Mr. TANG Ke

    Non-executive director

  • Mr. PU Tianruo

    Independent non-executive director

  • Dr. David Ross PARKINSON

    Independent non-executive director

  • Dr. WONG Lap Yan

    Independent non-executive director

  • Audit Committee

    We have established a Audit Committee in accordance with the Corporate Governance Code contained in Article 3.21 of Listing Rules and Appendix 14 of Listing Rules. The main responsibilities of the Audit Committee are to review and supervise the Company's financial reporting process and internal control system, review and approve connected transactions and provide advice to the Board. The Audit Committee currently comprises three members, including a non-executive director, namely Mr. HUANG Bin, and two independent non-executive Directors, namely, Mr. PU Tianruo (Chairman) and Dr. WONG Lap Yan. The chairman of the committee, Mr. Pu Tianruo, holds the appropriate qualifications as stipulated in Articles 3.10(2) and 3.21 of Listing Rules.

  • Remuneration Committee

    We have established a Remuneration Committee in accordance with the Corporate Governance Code contained in Article 3.25 of Listing Rules and Appendix 14 of Listing Rules. The main responsibilities of the Remuneration Committee are to review the terms of compensation plans, bonuses and other compensation payable to directors and senior management and make recommendations to the board in this regard. The Remuneration Committee currently comprises three members, including two independent non-executive Directors, namely Dr. WONG Lap Yan (Chairman) and Mr. PU Tianruo, and a non-executive Director, namely Mr. TANG Ke.

  • Nominations Committee

    We have established a Nominations Committee in accordance with the Corporate Governance Code contained in Appendix 14 of Listing Rules. The main responsibilities of the Nominations Committee are to make recommendations to the Board on the appointment of directors and the succession of the board of directors. The Nomination Committee currently comprises three members, including an executive Director, Dr. LOU Jing (Chairman), and two independent non-executive Directors, namely, Mr. PU Tianruo and Dr. WONG Lap Yan.

Corporate Governance Documents

The Company has adopted the Corporate Governance Code (the “CG Code”) contained in Appendix 14 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the“Listing Rules”) as its own code of corporate governance.
The Company has adopted the Model Code as set out in Appendix 10 of the Listing Rules as its own code of conduct regarding Directors’ securities transactions.